Возможности применения тадалафила в лечении сексуальных расстройств

2. Alwaal A, Breyer BN, Lue TF. Normal male sexual function: emphasis on orgasm and ejaculation 2015; 104 (5): 1051–60. DOI: 10.1016 / j.fertnstert.2015.08.033 [in Russian]
3. Bansal UK, Jones C, Fuller TW et al. The Efficacy of Tadalafil Daily vs on Demand in the Treatment of Erectile Dysfunction: A Systematic Review and Meta-analysis. Urology 2017. pii: S0090-4295(17)30905-6. DOI: 10.1016/j.urology.2017.08.031
4. Choi H, Kim JH, Shim JS et al. Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms. Int J Impot Res 2015; 27 (1): 33–7. DOI: 10.1038/ijir.2014.19
5. Chou PS, Chou WP, Chen MC et al. Newly diagnosed erectile dysfunction and risk of depression: a population-based 5-year follow-up study in Taiwan. J Sex Med 2015; 12 (3): 804–12. DOI: 10.1111/jsm.12792.
6. Corona G, Mondaini N, Ungar A et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: The proper drug for the proper patient. J Sex Med 2011; 8: 3418–32.
7. Corona G, Petrone L, Mannucci E et al. Psycho-biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. Eur Urol 2004; 46: 615–22. DOI: 10.1016/j.eururo.2004.07.001
8. Corona G, Wu FC, Rastrelli G et al. Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS). J Sex Med 2014; 11 (1): 240–53. DOI: 10.1111/jsm.12327
9. El-Sakka AI. Severity of erectile dysfunction at presentation: effect of premature ejaculation and low desire. Urology 2008; 71 (1): 94–8. DOI: 10.1016/j.urology.2007.09.006
10. Grimsley SJ, Khan MH, Jones GE. Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms. Med Hypotheses 2007; 69 (1): 25–6. DOI: 10.1016/j.mehy.2006.11.040
11. Hellstrom WJ, Overstreet JW, Yu A et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urology 2003; 170 (3): 887–91. DOI: 10.1097/01.ju.0000081053.97792.da
12. Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urology 1982; 54 (6): 729–31. DOI: 10.1111/j.1464-410X. 1982.tb13635.x
13. La Vignera S, Condorelli RA, Mongioi LM, Calogero AE. Chronic Administration of Tadalafil Improves the Symptoms of Patients with Amicrobic MAGI: An Open Study. Int J Endocrinol 2017; 2017: 3848545. DOI: 10.1155/2017/3848545
14. La Vignera S, Vicari E, Condorelli R et al. Hypertrophic-congestive and fibro-sclerotic ultrasound variants of male accessory gland infection have different sperm output. J Endocrinol Invest 2011; 34 (10): e330–e335. DOI: 10.1007/BF03346729
15. McMahon C.G. Original research – ejaculatory disorders: Screening for Erectile Dysfunction in Men with Lifelong Premature Ejaculation. Is the Sexual Health Inventory for Men (SHIM) Reliable? J Sex Med. 2009; 6 (2): 567-573. DOI: 10.1111 / j.1743-6109.2008.01092.x
16. McMahon C. Comparison of Efficacy, Safety, and Tolerability of On – Demand Tadalafil and Daily Dosed Tadalafil for the Treatment of Erectile Dysfunction. J Sex Med 2005; 2 (3): 415-427. DOI: 10.1111 / j.1743-6109.2005.20360.x
17. Nicolosi A, Moreira ED, Villa M, Glasser DB. A population study of the association between sexual function, sexual satisfaction and depressive symptoms in men. J Affect Dis 2004; 82: 235–43. DOI: 10.1016/j.jad.2003.12.008
18. Ozcan L, Polat EC, Onen E et al. Effects of tadalafil 5 mg dosed once daily in men with premature ejaculation. Urol Int 2017; 98 (2): 210–4. DOI: 10.1159/000445839
19. Peng Z, Yang L, Dong Q et al. Efficacy and Safety of Tadalafil Once-a-Day versus Tadalafil On-Demand in Patients with Erectile Dysfunction: A Systematic Review and Meta-Analyses. Urol Int 2017; 99 (3): 343–52. DOI: 10.1159/000477496
20. Pizzi C, Manzoli L, Mancini S, Costa GM. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur Heart J 2008; 29 (9): 1110–7. DOI: 10.1093 / eurheartj / ehn137
21. Porst H, McMahon CG, Althof SE et al. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials. J Sex Med 2010; 7 (6): 2231–42. DOI: 10.1111/j.1743-6109.2010.01820.x
22. Porst H, Gacci M, Büttner H et al. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. Eur Urol 2014; 65 (2): 455–64. DOI: 10.1016/j.eururo.2013.09.037
23. Porst H, Montorsi F, Rosen RC et al. The premature ejaculation prevalence and attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol 2007; 51: 816–23. Discussion 824.
24. Rubio-Aurioles E, Porst H, Kim ED et al. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 2012; 9 (5): 1418–29. DOI: 10.1111/j.1743-6109.2012.02667.x
25. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171 (1): 2341–5.
26. Seidman SN, Roose SP, Menza MA et al. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001; 158 (10): 1623–30. DOI: 10.1176/appi.ajp.158.10.1623
27. Shabsigh R, Seftel AD, Rosen RC et al. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology 2006; 68 (4): 689–96. DOI: 10.1016/j.urology.2006.05.009
28. Setter SM, Iltz JL, Fincham JE et al. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother 2005; 39 (7–8): 1286–95. DOI: 10.1345/aph.1E487
29. Shim YS, Pae CU, Cho KJ et al. Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study. Int J Impot Res 2014; 26 (2): 76–80. DOI: 10.1038/ijir.2013.38
30. Sontag A, Ni X, Althof SE, Rosen RC. Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil. Int J Impot Res 2014; 26 (1): 7–12. DOI: 10.1038/ijir.2013.31
31. Taylor MJ, Rudkin L, Bullemor-Day P et al. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev 2013; 5: CD003382. DOI: 10.1002/14651858.CD003382.pub3
32. Yafi FA, Jenkins L, Albersen M et al. Erectile dysfunction. Nat Rev Dis Primers 2016; 2: 16003. DOI: 10.1038/nrdp.2016.3
33. Wang R, Burnett AL, Heller WH et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med 2012; 9 (8): 2122–9. DOI: 10.1111/j.1743-6109.2012.02822.x
34. Wayman C, Phillips S, Lunny C et al. Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. Int J Impot Res 2005; 17 (3): 216–23. DOI: 10.1038/sj.ijir.3901307
35. Wrishko R, Sorsaburu S, Wong D et al. Safety, Efficacy, and Pharmacokinetic Overview of Low-Dose Daily Administration of Tadalafil. J Sex Med 2009; 6 (7): 2039–48. DOI: 10.1111 / j.1743-6109.2009.01301.x
36. Ахвледиани Н.Д. Лечение вторичной преждевременной эякуляции, связанной с эректильной дисфункцией. Мед. совет. 2016; 5: 94–7. / Ahvlediani N.D. Lechenie vtorichnoj prezhdevremennoj eyakulyacii, svyazannoj s erektil'noj disfunkciej. Med. sovet. 2016; 5: 94–7. [in Russian]
37. Буват Дж. Pathophysiology of premature ejaculation. J Sex Med 2011; 8 (4): 316–27. DOI: 10.1111 / j.1743-6109.2011.02384.x / Buvat Dzh. Pathophysiology of premature ejaculation. J Sex Med 2011; 8 (4): 316–27. DOI: 10.1111 / j.1743-6109.2011.02384.x
38. Верткин А.Л., Пушкарь Д.Ю., Тополянский А.В., Сегал А.С. Эректильная дисфункция. Лечащий врач. 2003; 7: 54–60. / Vertkin A.L., Pushkar' D.Yu., Topolyanskij A.V., Segal A.S. Erektil'naya disfunkciya. Lechashchij vrach. 2003; 7: 54–60. [in Russian]
39. Gandaglia G, Briganti A, Jackson G et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol 2014; 65 (5): 968–78. DOI: 10.1016 / j.eururo.2013.08.023
40. Гамидов С.И., Щербаков Д.В., Тажетдинов О.Х. и др. Эффективность тадалафила у пациентов с преждевременной эякуляцией в сочетании с эректильной дисфункцией. Вестн. Рос. гос. мед. ун-та. 2010; 6: 54–8. / Gamidov S.I., Shcherbakov D.V., Tazhetdinov O.H. i dr. Effektivnost' tadalafila u pacientov s prezhdevremennoj eyakulyaciej v sochetanii s erektil'noj disfunkciej. Vestn. Ros. gos. med. un-ta. 2010; 6: 54–8. [in Russian]
41. Giuliano F, Oelke M, Jungwirth A et al. Tadalafil Once Daily Improves Ejaculatory Function, Erectile Function, and Sexual Satisfaction in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Erectile Dysfunction: Results from a Randomized, Placebo- and Tamsulosin-ontrolled, 12-Week Double-Blind Study. J Sex Med 2013; 10 (3): 857-865. DOI: 10.1111 / jsm.12039
42. Ефремов Е.А., Дорофеев С.Д., Панюшкин С.М., Бедретдинова Д.А. Сексуальные и психосоматические расстройства при хроническом простатите. Мед. совет. 2008; 9–10: 30–6. / Efremov E.A., Dorofeev S.D., Panyushkin S.M., Bedretdinova D.A. Seksual'nye i psihosomaticheskie rasstrojstva pri hronicheskom prostatite. Med. sovet. 2008; 9–10: 30–6. [in Russian]
43. Комлев Д.С., Ямлихина Е.Г., Сайфуллина Л.И. и др. Возможности медицинской коррекции психологического статуса пациентов с артериальной гипертензией с эректильной дисфункцией. Мед. вестн. Башкортостана. 2011; 6 (6): 53–7. / Komlev D.S., Yamlihina E.G., Sajfullina L.I. i dr. Vozmozhnosti medicinskoj korrekcii psihologicheskogo statusa pacientov s arterial'noj gipertenziej s erektil'noj disfunkciej. Med. vestn. Bashkortostana. 2011; 6 (6): 53–7. [in Russian]
44. Клочай В.В., Крупин В.Н. Роль психоэмоциональных нарушений в патогенезе эректильной дисфункции при цереброваскулярных заболеваниях. Мед. альманах. 2010; 2: 61–5. / Klochaj V.V., Krupin V.N. Rol' psihoemocional'nyh narushenij v patogeneze erektil'noj disfunkcii pri cerebrovaskulyarnyh zabolevaniyah. Med. al'manah. 2010; 2: 61–5. [in Russian]
45. Corvasce A, Albino G, Leonetti T et al. Once-a-day Tadalafil administration improves the spermogram parameters in fertile patients. Arch Ital Urol Androl 2015; 87 (3): 210–3. DOI: 10.4081 / aiua.2015.3.210
46. Paduch DA, Bolyakov A, Beardsworth A, Watts SD. Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil. BJU Int 2012; 109 (7): 1060–7. DOI: 10.1111 / j.1464-410X.2011.10504.x
47. Paduch DA, Bolyakov A, Polzer PK, Watts SD. Effects of 12 weeks of tadalafil treatment on ejaculatory and orgasmic dysfunction and sexual satisfaction in patients with mild to severe erectile dysfunction: integrated analysis of 17 placebo-controlled studies. BJU Int 2013; 111 (2): 334–43. DOI: 10.1111 / j.1464-410X.2012.11656.x
48. Scranton RE, Goldstein I, Stecher VJ. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. J Sex Med 2013; 10 (2): 551–61. DOI: 10.1111 / j.1743-6109.2012.02998.x
49. Хера М. Пациенты с синдромом дефицита тестостерона и депрессией. Arch Esp Urol 2013; 66 (7): 729–36. / Hera M. Pacienty s sindromom deficita testosterona i depressiej. Arch Esp Urol 2013; 66 (7): 729–36. [in Russian]
50. Shiri R, Koskimäki J, Tammela TL et al. Bidirectional relationship between depression and erectile dysfunction. J Urol 2007; 177 (2): 669–73. DOI: 10.1016 / j.juro.2006.09.030
51. Yao F, Huang Y, Zhang Y et al. Subclinical endothelial dysfunction and low-grade inflammation play roles in the development of erectile dysfunction in young men with low risk of coronary heart disease. Int J Androl 2012; 35 (5): 653–9. DOI: 10.1111 / j.1365-2605.2012.01273.x
52. Инструкция по применению лекарственного препарата для медицинского применения Динамико Лонг. / Instrukciya po primeneniyu lekarstvennogo preparata dlya medicinskogo primeneniya Dinamiko Long. [in Russian]
53. Porst H, Padma-Nathan H, Giuliano G et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 121–125.

________________________________________________

1. Althof SE, McMahon CG, Waldinger MD et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). J Sex Med 2014; 11 (6): 1392–422. DOI: 10.1111 / jsm.12504
2. Alwaal A, Breyer BN, Lue TF. Normal male sexual function: emphasis on orgasm and ejaculation 2015; 104 (5): 1051–60. DOI: 10.1016 / j.fertnstert.2015.08.033 [in Russian]
3. Bansal UK, Jones C, Fuller TW et al. The Efficacy of Tadalafil Daily vs on Demand in the Treatment of Erectile Dysfunction: A Systematic Review and Meta-analysis. Urology 2017. pii: S0090-4295(17)30905-6. DOI: 10.1016/j.urology.2017.08.031
4. Choi H, Kim JH, Shim JS et al. Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms. Int J Impot Res 2015; 27 (1): 33–7. DOI: 10.1038/ijir.2014.19
5. Chou PS, Chou WP, Chen MC et al. Newly diagnosed erectile dysfunction and risk of depression: a population-based 5-year follow-up study in Taiwan. J Sex Med 2015; 12 (3): 804–12. DOI: 10.1111/jsm.12792.
6. Corona G, Mondaini N, Ungar A et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: The proper drug for the proper patient. J Sex Med 2011; 8: 3418–32.
7. Corona G, Petrone L, Mannucci E et al. Psycho-biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. Eur Urol 2004; 46: 615–22. DOI: 10.1016/j.eururo.2004.07.001
8. Corona G, Wu FC, Rastrelli G et al. Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS). J Sex Med 2014; 11 (1): 240–53. DOI: 10.1111/jsm.12327
9. El-Sakka AI. Severity of erectile dysfunction at presentation: effect of premature ejaculation and low desire. Urology 2008; 71 (1): 94–8. DOI: 10.1016/j.urology.2007.09.006
10. Grimsley SJ, Khan MH, Jones GE. Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms. Med Hypotheses 2007; 69 (1): 25–6. DOI: 10.1016/j.mehy.2006.11.040
11. Hellstrom WJ, Overstreet JW, Yu A et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urology 2003; 170 (3): 887–91. DOI: 10.1097/01.ju.0000081053.97792.da
12. Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urology 1982; 54 (6): 729–31. DOI: 10.1111/j.1464-410X. 1982.tb13635.x
13. La Vignera S, Condorelli RA, Mongioi LM, Calogero AE. Chronic Administration of Tadalafil Improves the Symptoms of Patients with Amicrobic MAGI: An Open Study. Int J Endocrinol 2017; 2017: 3848545. DOI: 10.1155/2017/3848545
14. La Vignera S, Vicari E, Condorelli R et al. Hypertrophic-congestive and fibro-sclerotic ultrasound variants of male accessory gland infection have different sperm output. J Endocrinol Invest 2011; 34 (10): e330–e335. DOI: 10.1007/BF03346729
15. McMahon C.G. Original research – ejaculatory disorders: Screening for Erectile Dysfunction in Men with Lifelong Premature Ejaculation. Is the Sexual Health Inventory for Men (SHIM) Reliable? J Sex Med. 2009; 6 (2): 567-573. DOI: 10.1111 / j.1743-6109.2008.01092.x
16. McMahon C. Comparison of Efficacy, Safety, and Tolerability of On – Demand Tadalafil and Daily Dosed Tadalafil for the Treatment of Erectile Dysfunction. J Sex Med 2005; 2 (3): 415-427. DOI: 10.1111 / j.1743-6109.2005.20360.x
17. Nicolosi A, Moreira ED, Villa M, Glasser DB. A population study of the association between sexual function, sexual satisfaction and depressive symptoms in men. J Affect Dis 2004; 82: 235–43. DOI: 10.1016/j.jad.2003.12.008
18. Ozcan L, Polat EC, Onen E et al. Effects of tadalafil 5 mg dosed once daily in men with premature ejaculation. Urol Int 2017; 98 (2): 210–4. DOI: 10.1159/000445839
19. Peng Z, Yang L, Dong Q et al. Efficacy and Safety of Tadalafil Once-a-Day versus Tadalafil On-Demand in Patients with Erectile Dysfunction: A Systematic Review and Meta-Analyses. Urol Int 2017; 99 (3): 343–52. DOI: 10.1159/000477496
20. Pizzi C, Manzoli L, Mancini S, Costa GM. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur Heart J 2008; 29 (9): 1110–7. DOI: 10.1093 / eurheartj / ehn137
21. Porst H, McMahon CG, Althof SE et al. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials. J Sex Med 2010; 7 (6): 2231–42. DOI: 10.1111/j.1743-6109.2010.01820.x
22. Porst H, Gacci M, Büttner H et al. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. Eur Urol 2014; 65 (2): 455–64. DOI: 10.1016/j.eururo.2013.09.037
23. Porst H, Montorsi F, Rosen RC et al. The premature ejaculation prevalence and attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol 2007; 51: 816–23. Discussion 824.
24. Rubio-Aurioles E, Porst H, Kim ED et al. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 2012; 9 (5): 1418–29. DOI: 10.1111/j.1743-6109.2012.02667.x
25. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171 (1): 2341–5.
26. Seidman SN, Roose SP, Menza MA et al. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001; 158 (10): 1623–30. DOI: 10.1176/appi.ajp.158.10.1623
27. Shabsigh R, Seftel AD, Rosen RC et al. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology 2006; 68 (4): 689–96. DOI: 10.1016/j.urology.2006.05.009
28. Setter SM, Iltz JL, Fincham JE et al. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother 2005; 39 (7–8): 1286–95. DOI: 10.1345/aph.1E487
29. Shim YS, Pae CU, Cho KJ et al. Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study. Int J Impot Res 2014; 26 (2): 76–80. DOI: 10.1038/ijir.2013.38
30. Sontag A, Ni X, Althof SE, Rosen RC. Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil. Int J Impot Res 2014; 26 (1): 7–12. DOI: 10.1038/ijir.2013.31
31. Taylor MJ, Rudkin L, Bullemor-Day P et al. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev 2013; 5: CD003382. DOI: 10.1002/14651858.CD003382.pub3
32. Yafi FA, Jenkins L, Albersen M et al. Erectile dysfunction. Nat Rev Dis Primers 2016; 2: 16003. DOI: 10.1038/nrdp.2016.3
33. Wang R, Burnett AL, Heller WH et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med 2012; 9 (8): 2122–9. DOI: 10.1111/j.1743-6109.2012.02822.x
34. Wayman C, Phillips S, Lunny C et al. Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. Int J Impot Res 2005; 17 (3): 216–23. DOI: 10.1038/sj.ijir.3901307
35. Wrishko R, Sorsaburu S, Wong D et al. Safety, Efficacy, and Pharmacokinetic Overview of Low-Dose Daily Administration of Tadalafil. J Sex Med 2009; 6 (7): 2039–48. DOI: 10.1111 / j.1743-6109.2009.01301.x
36. Ahvlediani N.D. Lechenie vtorichnoj prezhdevremennoj eyakulyacii, svyazannoj s erektil'noj disfunkciej. Med. sovet. 2016; 5: 94–7. [in Russian]
37. Buvat Dzh. Pathophysiology of premature ejaculation. J Sex Med 2011; 8 (4): 316–27. DOI: 10.1111 / j.1743-6109.2011.02384.x
38. Vertkin A.L., Pushkar' D.Yu., Topolyanskij A.V., Segal A.S. Erektil'naya disfunkciya. Lechashchij vrach. 2003; 7: 54–60. [in Russian]
39. Gandaglia G, Briganti A, Jackson G et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol 2014; 65 (5): 968–78. DOI: 10.1016 / j.eururo.2013.08.023
40. Gamidov S.I., Shcherbakov D.V., Tazhetdinov O.H. i dr. Effektivnost' tadalafila u pacientov s prezhdevremennoj eyakulyaciej v sochetanii s erektil'noj disfunkciej. Vestn. Ros. gos. med. un-ta. 2010; 6: 54–8. [in Russian]
41. Giuliano F, Oelke M, Jungwirth A et al. Tadalafil Once Daily Improves Ejaculatory Function, Erectile Function, and Sexual Satisfaction in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Erectile Dysfunction: Results from a Randomized, Placebo- and Tamsulosin-ontrolled, 12-Week Double-Blind Study. J Sex Med 2013; 10 (3): 857-865. DOI: 10.1111 / jsm.12039
42. Efremov E.A., Dorofeev S.D., Panyushkin S.M., Bedretdinova D.A. Seksual'nye i psihosomaticheskie rasstrojstva pri hronicheskom prostatite. Med. sovet. 2008; 9–10: 30–6. [in Russian]
43. Komlev D.S., Yamlihina E.G., Sajfullina L.I. i dr. Vozmozhnosti medicinskoj korrekcii psihologicheskogo statusa pacientov s arterial'noj gipertenziej s erektil'noj disfunkciej. Med. vestn. Bashkortostana. 2011; 6 (6): 53–7. [in Russian]
44. Klochaj V.V., Krupin V.N. Rol' psihoemocional'nyh narushenij v patogeneze erektil'noj disfunkcii pri cerebrovaskulyarnyh zabolevaniyah. Med. al'manah. 2010; 2: 61–5. [in Russian]
45. Corvasce A, Albino G, Leonetti T et al. Once-a-day Tadalafil administration improves the spermogram parameters in fertile patients. Arch Ital Urol Androl 2015; 87 (3): 210–3. DOI: 10.4081 / aiua.2015.3.210
46. Paduch DA, Bolyakov A, Beardsworth A, Watts SD. Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil. BJU Int 2012; 109 (7): 1060–7. DOI: 10.1111 / j.1464-410X.2011.10504.x
47. Paduch DA, Bolyakov A, Polzer PK, Watts SD. Effects of 12 weeks of tadalafil treatment on ejaculatory and orgasmic dysfunction and sexual satisfaction in patients with mild to severe erectile dysfunction: integrated analysis of 17 placebo-controlled studies. BJU Int 2013; 111 (2): 334–43. DOI: 10.1111 / j.1464-410X.2012.11656.x
48. Scranton RE, Goldstein I, Stecher VJ. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. J Sex Med 2013; 10 (2): 551–61. DOI: 10.1111 / j.1743-6109.2012.02998.x
49. Hera M. Pacienty s sindromom deficita testosterona i depressiej. Arch Esp Urol 2013; 66 (7): 729–36. [in Russian]
50. Shiri R, Koskimäki J, Tammela TL et al. Bidirectional relationship between depression and erectile dysfunction. J Urol 2007; 177 (2): 669–73. DOI: 10.1016 / j.juro.2006.09.030
51. Yao F, Huang Y, Zhang Y et al. Subclinical endothelial dysfunction and low-grade inflammation play roles in the development of erectile dysfunction in young men with low risk of coronary heart disease. Int J Androl 2012; 35 (5): 653–9. DOI: 10.1111 / j.1365-2605.2012.01273.x
52. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicinskogo primeneniya Dinamiko Long. [in Russian]
53. Porst H, Padma-Nathan H, Giuliano G et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 121–125.

А.Ю.Цуканов*, А.С.Кутуков

ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России. 644043, Россия, Омск, ул. Ленина, д. 12
*tsoukanov2000@mail.ru

________________________________________________

*tsoukanov2000@mail.ru